![IJMS | Free Full-Text | Herpes Simplex Virus Oncolytic Immunovirotherapy: The Blossoming Branch of Multimodal Therapy IJMS | Free Full-Text | Herpes Simplex Virus Oncolytic Immunovirotherapy: The Blossoming Branch of Multimodal Therapy](https://www.mdpi.com/ijms/ijms-21-08310/article_deploy/html/images/ijms-21-08310-g001.png)
IJMS | Free Full-Text | Herpes Simplex Virus Oncolytic Immunovirotherapy: The Blossoming Branch of Multimodal Therapy
![2011 AIMS: New HSV Black Edition Versions of Commodore Based Sedan, Station and Ute Models | Carscoops 2011 AIMS: New HSV Black Edition Versions of Commodore Based Sedan, Station and Ute Models | Carscoops](https://www.carscoops.com/wp-content/uploads/2011/07/HSVSVBlackRange11.jpg)
2011 AIMS: New HSV Black Edition Versions of Commodore Based Sedan, Station and Ute Models | Carscoops
![Arming HSV-Based Oncolytic Viruses with the Ability to Redirect the Host's Innate Antiviral Immunity to Attack Tumor Cells: Molecular Therapy - Oncolytics Arming HSV-Based Oncolytic Viruses with the Ability to Redirect the Host's Innate Antiviral Immunity to Attack Tumor Cells: Molecular Therapy - Oncolytics](https://www.cell.com/cms/attachment/e1527b51-29fd-41aa-b4d7-b596a9acd10f/fx1_lrg.jpg)
Arming HSV-Based Oncolytic Viruses with the Ability to Redirect the Host's Innate Antiviral Immunity to Attack Tumor Cells: Molecular Therapy - Oncolytics
![Herpes simplex virus-2 transmission probability estimates based on quantity of viral shedding | Journal of The Royal Society Interface Herpes simplex virus-2 transmission probability estimates based on quantity of viral shedding | Journal of The Royal Society Interface](https://royalsocietypublishing.org/cms/asset/74329518-a3d7-488c-b2a8-7c441403730a/rsif20140160f01.jpg)
Herpes simplex virus-2 transmission probability estimates based on quantity of viral shedding | Journal of The Royal Society Interface
![Mathematical modeling of herpes simplex virus-2 suppression with pritelivir predicts trial outcomes | Science Translational Medicine Mathematical modeling of herpes simplex virus-2 suppression with pritelivir predicts trial outcomes | Science Translational Medicine](https://www.science.org/cms/10.1126/scitranslmed.aad6654/asset/776d795d-2da8-4a4b-a185-54f4ab7b1b43/assets/graphic/8-324ra15-f3.jpeg)